Seroprevalence of COVID-19 antibody among patients visiting a large clinic in Uttar Pradesh
Keywords:SARS-CoV-2, COVID-19, Seroprevalence
Background: The study was conducted to determine the Coronavirus disease 2019 (COVID-19) antibody titre among patients who visited our clinic in Lucknow in order to find out the prevalence of sero positivity and to determine the association between COVID anti-body titre and positivity to different age groups, sex, and religions etc., if any.
Methods: Secondary data analysis was conducted at Lucknow's Sitara polyclinic from patients’ data, who had attended the clinic between May 2021 and July 2021 and had universally undergone COVID antibody testing. COVID antibody (including IgG) levels in patients' blood were determined using Roche's commercial "Elecsys Anti-SARS-CoV2-cobas e411,601,602 system.by Roche which measure by Eclia (electro chemilusence immunoassay) quantitatively antibodies (including IgG). Patients with titres less than 1 u/ml were deemed seronegative for anti –SARS COVID-2, while those with titres greater than or equal to 1 u/ml were declared seropositive.
Results: The overall rate of seropositivity was 84.8%. Around 84.5% males and 85.1% females were seropositive. Seropositivity was higher among 18 to 60 years of age. But there was no significant relation between mean age and seropositivity. Muslims had slightly higher seropositivity (86.0%) as compared to non-Muslims (84.5%). There was no significant difference between age and gender having positive COVID 19 antibody titres. Although the incidence of seropositivity was similar between Muslims and Non-Muslims, the antibody titres were significantly higher in Muslim patients.
Conclusions: In this part of central eastern UP, incidence of seropositivity could already be as high as 85%, which is a pointer toward adequate herd immunity. COVID-19 does not differentiate on the basis of age, gender or religious affiliations. However, Muslims were found to have more antibody titres compared to non-Muslims, possibly related to life style, degree of exposure to COVID-19 virus and presence of inherent immunity.
Chams N, Chams S, Badran R, Shams A, Araji A, Raad M et al. COVID-19: a multidisciplinary review. Frontiers in public health. 2020;8:383.
Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Annals of internal medicine. 2020173(5):362-7.
Bai Y, Yao L, Wei T. Presumed asymptomatic carrier transmission of COVID-19. JAMA;2020.
Zou L, Ruan F, Huang M. SARS-CoV-2 viral load in upper respiratory specimaless of infected patients [Letter]. N Engl J Med. 2020;382:1177-9.
Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH et al. The implications of silent transmission for the control of COVID-19 outbreaks. Proceedings of the National Academy of Sciences. 2020;117(30):17513-5.
Wu J, Liu X, Zhou D, Qiu G, Dai M, Yang Q et al. Identification of RT-PCR-negative asymptomatic COVID-19 patients via serological testing. Frontiers in public health. 2020;8:267.
CDC. COVID-19 Serology Surveillance Strategy. Cited through Available at: https://www.cdc.gov/coronavirus/2019-ncov/COVID-data/serology-surveillance/index.html. Accessed on 12th October 2021.
World Health Organization. Coordinated global research roadmap: 2019 novel coronavirus; March 2020. Geneva: WHO; 2020. Available at: https://www.who.int/blueprint/priority-diseases/key-action/Coronavirus_Roadmap_V9.pdf. Accessed on 12th October 2021.
Kumar MS, Bhatnagar T, Manickam P, Kumar VS, Rade K, Shah N et al. National sero-surveillance to monitor the trend of SARS-CoV-2 infection transmission in India: Protocol for community-based surveillance. The Indian Journal of Medical Research. 2020;151(5):419.
TNN / Apr 4, 2021. (n.d.). Lucknow: Second wave of COVID-19 pandemic 3.5 times faster than 2020 surge: Lucknow News - Times of India. The Times of India. Available at: https://timesofindia.indiatimes.com/city/lucknow/lucknow-second-wave-of-COVID-19-pandemic-3-5-times-faster-than-2020-surge/articleshow/81893359.cms. Accessed on 12 October 2021.
Huang AT, Garcia-Carreras B, Hitchings MD, Yang B, Katzelnick LC, Rattigan SM et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nature communications. 2020;11(1):1-6.
Velumani A, Nikam C, Suraweera W, Fu SH, Gelband H, Brown PE et al. SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020. medRxiv. 2020.
Nagargoje B, Palod A, Dixit J, Yelikar K, Andurkar S, Badgujar S. Seroprevalence of COVID-19 in a City in India: A Community-based Cross-Sectional Study. J Res Med Dent Sci. 2021;9(9):48-53.
Dixit JV, Iravane J, Andurkar SP. Seroprevalence of COVID-19 in Aurangabad district. IJCRT. 2020;8 (9):3675-83.
Saple P, Gosavi S, Pawar T, Chaudhari G, Mahale H, Deshmukh P, et al. Seroprevalence of anti-SARS-CoV-2 of IgG antibody by ELISA: Community-based, cross-sectional study from urban area of Malegaon, Maharashtra. J Family Med Prim Care. 2021;10:1453-8.
Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, immunity, and COVID-19: how age influences the host immune response to coronavirus infections?. Frontiers in Physiology. 2021;11:1793.
Jin JM, Bai P, He W, Wu F, Liu XF, Han DM et al. Gender differences in patients with COVID-19: focus on severity and mortality. Frontiers in public health. 2020;8:152.
Bhatia R, Abraham P. The enigmatic COVID-19 pandemic. The Indian Journal of Medical Research. 2020;152(1-2):1.
Bwire GM. Coronavirus: why males are more vulnerable to COVID-19 than women? SN comprehensive clinical medicine. 2020;2(7):874-6.